Cell/Gene Tx channel feed

J&J takes vic­to­ry lap on its Carvyk­ti da­ta. But how many pa­tients will take it — and when? #AS­CO23

Yesterday
R&D

Take­da ax­es gene ther­a­py deal with Po­sei­da Ther­a­peu­tics amid broad­er re­think

4 days ago
Deals

Pre­ci­sion Bio­Sciences to meet with FDA af­ter tout­ing al­lo­gene­ic CAR-T win

5 days ago
R&D

RA Cap­i­tal-backed non-vi­ral gene ther­a­py start­up Sum­ma­tion Bio to shut down

6 days ago
People

With cash run­ning low, Swedish cell ther­a­py com­pa­ny looks to sell off plat­form

Last week
R&D

Out­pace Bio ex­pands cell ther­a­py R&D, nets re­search col­lab­o­ra­tions in Seat­tle

Last week
R&D

Rich Hor­gan spear­head­ed a gene ther­a­py for his broth­er. The tri­al end­ed in tragedy, but the work con­tin­ues for more pa­tients

Last week
In Focus

UCB en­ters gene ther­a­py space, ink­ing li­cense agree­ment for epilep­sy and neu­rode­gen­er­a­tion re­search

Last week
Deals

FDA de­lays Sarep­ta's Duchenne gene ther­a­py de­ci­sion by a month

Last week
R&D

PTC cuts gene ther­a­py pro­grams, dis­clos­es PhI­II fail in Friedre­ich's atax­ia and CFO ex­it

Last week
R&D

El­e­vate­Bio snags the year's largest raise with $401M Se­ries D, plus a re­search part­ner­ship with No­vo

Last week
Financing

In wake of Ru­bius down­fall, a new biotech spin­out launch­es to 'take the next step' in red blood cell ther­a­pies

2 weeks ago
Startups

No­var­tis beefs up gene ther­a­py pipeline, spend­ing $87.5M on an Avro­bio ther­a­py

2 weeks ago
Deals
Pharma

First-of-its-kind gene ther­a­py ap­proved for heal­ing wounds in “but­ter­fly chil­dren”

3 weeks ago
R&D
FDA+

CBER chief Pe­ter Marks to con­sid­er 'al­ter­na­tives' to clin­i­cal holds as they 'put shud­ders down in­vestors' spines'

3 weeks ago
FDA+

Af­ter rais­ing half a bil­lion dol­lars, a se­cre­tive biotech gives an ear­ly look at its gene edit­ing pipeline

3 weeks ago
R&D

Pa­tient who re­ceived cus­tom gene ther­a­py like­ly died from im­mune re­ac­tion, not CRISPR, pa­per says

3 weeks ago
R&D

Mus­tang Bio to sell Mass­a­chu­setts CAR-T man­u­fac­tur­ing fa­cil­i­ty

3 weeks ago
Deals
Manufacturing

As­traZeneca beefs up cell ther­a­py tool kit with gene edit­ing deal

3 weeks ago
Deals

Ex­clu­sive: Cell and gene ther­a­py biotech cre­ator Re­play plucks Al­lo­gene CMO Arun Bal­aku­maran to lead clin­i­cal tri­als

3 weeks ago
People

FDA's Pe­ter Marks talks re­im­burse­ment of gene ther­a­pies that win ac­cel­er­at­ed ap­proval

3 weeks ago

SPAC for 2025 BLA: Non-vi­ral gene ther­a­py biotech en­Gene, steered by ex-Myth­ic lead­ers, finds For­bion blank check

3 weeks ago
Startups
Deals

Gilead woos Cindy Perettie from Roche to lead Kite af­ter Christi Shaw de­parts

3 weeks ago
People

Lil­ly’s Pre­vail taps Jen­nifer Doud­na's spin­out Scribe Ther­a­peu­tics for neu­ro ge­net­ic med­i­cines

3 weeks ago
Startups
Deals
1234 Next page Last page
A service from the Financial Times